spironolactone has been researched along with Amyloidosis in 10 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Amyloidosis: A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits.
| Excerpt | Relevance | Reference |
|---|---|---|
| "An enriched subset of patients with structural and functional echocardiographic features of cardiac amyloidosis had the worst prognosis in the TOPCAT study, but they benefitted similarly from spironolactone therapy." | 9.41 | Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis: Results From TOPCAT. ( Hanna, M; Jaber, WA; Shah, SJ; Sperry, BW; Spertus, JA, 2021) |
| "An enriched subset of patients with structural and functional echocardiographic features of cardiac amyloidosis had the worst prognosis in the TOPCAT study, but they benefitted similarly from spironolactone therapy." | 5.41 | Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis: Results From TOPCAT. ( Hanna, M; Jaber, WA; Shah, SJ; Sperry, BW; Spertus, JA, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (40.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sperry, BW | 1 |
| Hanna, M | 1 |
| Shah, SJ | 1 |
| Jaber, WA | 1 |
| Spertus, JA | 1 |
| Ageev, FT | 1 |
| Ovchinnikov, AG | 1 |
| Kim, MM | 1 |
| Prasad, M | 1 |
| Burton, Y | 1 |
| Kolseth, CM | 1 |
| Zhao, Y | 1 |
| Chandrashekar, P | 1 |
| Nazer, B | 1 |
| Masri, A | 1 |
| Schelbert, EB | 1 |
| Miller, CA | 1 |
| Wada, Y | 1 |
| Kobayashi, D | 1 |
| Murakami, S | 1 |
| Oda, M | 1 |
| Hanawa, H | 1 |
| Kuroda, T | 1 |
| Nakano, M | 1 |
| Narita, I | 1 |
| GILSANZ, V | 1 |
| BARRIO, E | 1 |
| CEBRIAN, L | 1 |
| ESTELLA, J | 1 |
| MAXWELL, MH | 1 |
| ADAMS, DA | 1 |
| GOLDMAN, R | 1 |
| Hoyer, RJ | 1 |
| Leung, N | 1 |
| Witzig, TE | 1 |
| Lacy, MQ | 1 |
| Steinitz, L | 1 |
| Schreiter, G | 1 |
| Clancy, RL | 1 |
| Stiel, JN | 1 |
1 trial available for spironolactone and Amyloidosis
| Article | Year |
|---|---|
Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis: Results From TOPCAT.
Topics: Amyloidosis; Echocardiography; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Phenot | 2021 |
9 other studies available for spironolactone and Amyloidosis
| Article | Year |
|---|---|
[Treatment of patients with heart failure and preserved ejection fraction: reliance on clinical phenotypes].
Topics: Aminobutyrates; Amyloidosis; Angiotensin Receptor Antagonists; Biphenyl Compounds; Heart Failure; Hu | 2022 |
Comparative Outcomes of a Transthyretin Amyloid Cardiomyopathy Cohort Versus Patients With Heart Failure With Preserved Ejection Fraction Enrolled in the TOPCAT Trial.
Topics: Amyloidosis; Cardiomyopathies; Heart Failure; Humans; Prealbumin; Spironolactone; Stroke Volume; Tre | 2023 |
Cardiac Amyloidosis as a Potential Confounder in Heart Failure With Preserved Ejection Fraction Trials.
Topics: Amyloidosis; Heart Failure; Humans; Natriuretic Peptides; Spironolactone; Stroke Volume | 2017 |
Cardiac AA amyloidosis in a patient with rheumatoid arthritis and systemic sclerosis: the therapeutic potential of biological reagents.
Topics: Aged; Amyloidosis; Antibodies, Antinuclear; Antirheumatic Agents; Arthritis, Rheumatoid; Benzimidazo | 2011 |
[PERITONEAL DIALYSIS (D.P.): ITS EFFICIENCY IN IRREDUCIBLE EDEMAS AFTER FAILURE OF OTHER TREATMENTS].
Topics: Amyloidosis; Bronchiectasis; Dialysis; Edema; Empyema; Heart Failure; Liver Cirrhosis; Nephrosis; Pe | 1963 |
CORTICOSTEROID THERAPY OF AMYLOID NEPHROTIC SYNDROME.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Aged; Amyloidosis; Biopsy; Chlorothiazide; Cho | 1964 |
Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis.
Topics: Amyloidosis; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Captopril; Ches | 2007 |
[Amyloidosis in childhood].
Topics: Amyloidosis; Child; Chronic Disease; Encephalomyelitis; Furosemide; Humans; Male; Nephrotic Syndrome | 1971 |
Familial Mediterranean fever with amyloidosis.
Topics: Adult; Amyloid; Amyloidosis; Bendroflumethiazide; Blood Proteins; Diet Therapy; Electrophoresis; Eth | 1968 |